Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

Main enrolled criteria:

Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using

Inclusion Criteria:

• ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
• HER 2 Insertion or Amplification
• First Diagnosis and Treatment
• Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody

Exclusion Criteria:

• Patients received antitumor treatment before
• Patients with contraindication of chemotherapy
• Pregnant or breast feeding women